Skip to main content

Table 2 Descriptive characteristics of the populations used in the follow-up association studies on incident cardiovascular (CVD) and coronary heart disease (CHD) events: Women’s Health Initiative (WHI) and Framingham Offspring Study (FOS)

From: DNA methylation biomarkers of myocardial infarction and cardiovascular disease

Variables

WHI

FOS CHD

FOS CVD

N = 1863

NA

N = 2266

NA

N = 2123

NA

Age

64.2 (7.03)

0

65.7 (8.82)

0

65.3 (8.66)

0

Sex, female, n (%)

1863 (100)

0

1284 (56.7)

0

1206 (56.8)

0

CHD, n (%)

914 (49.1)

0

106 (4.68)

0

_

_

CVD, n (%)

984 (52.8)

0

_

_

222 (10.5)

0

Smokers, n (%)

174 (9.46)

24

217 (9.62)

11

202 (9.56)

11

BMI, kg/m2*

29.8 (5.97)

11

28.1 (5.39)

8

28.0 (5.33)

6

Total cholesterol, mg/dl*

233 (42.3)

1

189 (36.2)

1

190 (35.8)

1

LDL-C, mg/dl*

152 (38.7)

31

107 (30.8)

2

108 (30.5)

2

HDL-C, mg/dl*

52.2 (13.2)

1

58.3 (18.3)

2

58.7 (18.3)

2

TG, mg/d

126 [93.0;176]

1

101 [73.0;140]

1

100 [73.0;139]

1

SBP, mmHg*

131 (17.5)

0

126 (16.9)

1

125 (16.7)

1

DBP, mmHg*

76.4 (9.27)

0

72.1 (9.99)

3

72.3 (9.92)

3

HTN treatment, n (%)

672 (45.9)

400

1025 (45.4)

7

927 (43.8)

6

Glucose, mg/dl

107 (38.3)

1

106 (21.8)

2

105 (21.5)

2

Diabetes, n (%)

319 (17.1)

0

307 (14.3)

126

266 (13.3)

119

  1. CHD, Coronary heart disease; CVD, Cardiovascular disease; BMI, Body mass index; LDL-C, Cholesterol in low-density lipoprotein; HDL-C, Cholesterol in high-density lipoprotein; TG, Triglycerides; SBP, Systolic blood pressure; DBP, Diastolic blood pressure; HTN: hypertension; Diabetes, defined as previous treatment or glycaemia ≥ 126 mg/dl
  2. Median (Interquartile range)
  3. *Mean (Standard deviation)